Who is affected by this change?

This affects Independence Blue Cross Neurology, Rheumatology providers on Commercial plans.

When does this change take effect?

This change is effective Apr 30, 2025.

Back to dashboard

CommercialCoverageMedium impact

08.01.68b, Inebilizumab-cdon (Uplizna)

Independence Blue Cross·Neurology, Rheumatology·Pharmacy

Effective date

Apr 30, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

A commercial policy for Inebilizumab-cdon (Uplizna), a specialty pharmacy drug, has been updated and reissued. This appears to be a routine policy reissuance with an effective date of April 30, 2025.

Action Required

Action needed

By April 30, 2025: Billing team should review the full policy details at the provided URL to understand any changes to coverage criteria, prior authorization requirements, or billing procedures for Inebilizumab-cdon (Uplizna). Coordinate with providers who prescribe this specialty drug to ensure compliance with updated policy terms.

Related policy hubs

Independence Blue Cross policies Neurology Rheumatology